Skip to main content
Equibles
VMD logo

VMD · Viemed Healthcare, Inc. · Metrics

Track VMD — free

Use VMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.13 +0.12 (+1.33%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$345.96M
Shares
37.89M
Volume · Nov 6 256.08K Avg daily vol (3M) 297.71K

VMD metrics

111 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.13
Market cap
$345.96M

Price action

23 metrics
Price change (1W)
-9.4%
Price change (30D)
-3.8%
Price change (3M)
-5.4%
Price change (6M)
-2.2%
Price change (YTD)
+21.3%
Price change (1Y)
+40.1%
Trailing year
Price change (5Y)
+48.2%
52-week high
$12.33
52-week low
$6.26
Change from 52-week high
-26.9%
Change from 52-week low
+43.9%
Annualized volatility
41.0%
Annualized volatility (3M)
37.2%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.5
RSI (14D)
40.9
Price vs SMA 50
-2.7%
Price vs SMA 200
-6.2%
Avg volume (3M)
305,693
Relative volume
1.3
Average dollar volume
$2.81M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
37.89M

Valuation

12 metrics
P / E (TTM)
23.7
Trailing earnings · reciprocal yield 4.2%
PEG ratio
1.1
EV / revenue
1.1×
reciprocal yield 92.2%
EV / EBITDA
6.3×
reciprocal yield 16.0%
EV / EBIT
14.0×
reciprocal yield 7.2%
P / sales
1.1×
reciprocal yield 90.9%
P / book
2.3
reciprocal yield 44.0%
FCF yield
6.3%
TTM · current market cap
Buyback yield
2.3%
P / FCF
16.0
reciprocal yield 6.3%
P / operating cash flow
6.3
reciprocal yield 15.8%
Earnings yield
4.5%

Historical valuation

8 metrics
P / E historical average (3Y)
27.7×
reciprocal yield 3.6%
P / E historical average (5Y)
31.9×
reciprocal yield 3.1%
EV / revenue historical average (3Y)
1.3×
reciprocal yield 74.3%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 64.2%
EV / EBIT historical average (3Y)
17.0×
reciprocal yield 5.9%
EV / EBIT historical average (5Y)
21.0×
reciprocal yield 4.8%
EV / EBITDA historical average (3Y)
13.2×
reciprocal yield 7.6%
EV / EBITDA historical average (5Y)
13.2×
reciprocal yield 7.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.3%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
57.4%
Operating margin
7.8%
Trailing 12 months
Net margin
5.0%
Gross profit (TTM)
$178.17M
Operating profit (TTM)
$24.09M
Net income (TTM)
$15.45M
Trailing 12 months
Diluted EPS (TTM)
$0.38
FCF margin
6.9%
Effective tax rate
29.2%

Per share

11 metrics
Revenue per diluted share (TTM)
$7.62
Gross profit per diluted share (TTM)
$4.37
Operating profit per diluted share (TTM)
$0.59
EBITDA per diluted share (TTM)
$1.33
Net income per diluted share (TTM)
$0.38
Operating cash flow per diluted share (TTM)
$1.32
Free cash flow per diluted share (TTM)
$0.53
Capital expenditures per diluted share (TTM)
$0.80
R&D per diluted share (TTM)
$0.05
Stock compensation per diluted share (TTM)
$0.23
Book value per share
$3.72

Growth

11 metrics
Revenue growth YoY
+12.2%
Year over year
Net income growth YoY
+32.0%
Revenue (TTM)
$310.37M
Trailing 12 months
EPS growth YoY
+22.2%
Shares change YoY
+1.7%
Year over year · more shares
Revenue CAGR (3Y)
+24.9%
Revenue CAGR (5Y)
+15.5%
EPS CAGR (3Y)
+32.2%
EPS CAGR (5Y)
-13.9%
FCF CAGR (3Y)
+35.0%
FCF CAGR (5Y)
-11.6%

Quality

14 metrics
Return on equity
10.3%
Return on assets
7.4%
Debt / equity
0.0
Current ratio
1.3
EBITDA (TTM)
$53.74M
Free cash flow (TTM)
$21.38M
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
-0.1
Return on invested capital
11.7%
Trailing 12 months
Net cash
$4.66M
Latest balance sheet
Cash & equivalents
$9.68M
Total assets
$207.63M
Total debt
$5.02M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$53.90M
Capital expenditures (TTM)
$32.52M
R&D (TTM)
$2.18M
SG&A (TTM)
$139.65M
Stock compensation (TTM)
$9.26M
R&D / revenue
0.7%
Stock compensation / revenue
3.0%

Ownership (13F)

9 metrics
13F filers
166
13F filer change QoQ
+16
Institutional ownership
67.4%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
21.6%
Private-fund adviser ownership
20.6%
Active holders' share change QoQ
+3.0%
Holder tenure
12.2
Price vs estimated holder cost
+40.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.0%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 6.4 days to cover
Days to cover
6.4d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1729149 CUSIP 92663R105 13F (30d) 67 filings 55 filers Visit website Investor relations